News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Lannett Company, Inc. Adds Paul Taveira to Board of Directors
May 11, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PHILADELPHIA--(BUSINESS WIRE)--Lannett Company, Inc. (NYSE Amex: LCI), a manufacturer of generic pharmaceuticals, today announced the appointment of Paul Taveira to its board of directors, expanding the company’s board to eight members.
Twitter
LinkedIn
Facebook
Email
Print
People
MORE ON THIS TOPIC
Funding
Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset
October 8, 2026
·
1 min read
·
Tristan Manalac
Layoff Tracker
Caribou to stop R&D work, start ‘substantial’ job cuts
October 8, 2026
·
100 min read
·
BioSpace Editorial Staff
Insights
Beyond equity: Why venture debt is reshaping European biotech
October 8, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Job Trends
Q3 layoffs down YOY, with 90% fewer biopharma employees affected
October 8, 2026
·
6 min read
·
Angela Gabriel
